When treating patients with type 2 diabetes, it is important to reduce the risk of developing Editcardiovascular disease (CVD). Previous studies have shown that higher HbA1c values are risk factors for CVD. However, previous studies have not shown that glycemic control or treatment with any oral hypoglycemic agent reduces incidence of CVD.
Alogliptin Prevents the Progression of Atherosclerosis in Type 2 Diabetes Patients
Posted in Drugs